A Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Participants With Low CA125 Platinum-sensitive Ovarian Cancer

Clinical trial NCT02289950 · COMPLETED

Trial details

NCT number: NCT02289950
Sponsor: Eisai Inc.
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Platinum-Sensitive Ovarian Cancer in First Relapse

Start date: 2015-03-19
Primary completion: 2019-05-31
Enrollment: 332

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.